Although CTLA-4 and PD-1/PD-L1 inhibitors have not shown robust clinical activity in AML, the addition of PD-1 inhibitors to intensive chemotherapy and HMAs achieved encouraging rates of MRD negative CR, suggesting their potential role in MRD eradication. Here, CD274 is linked to acute myeloid leukemia.